Last kr250.20 DKK
Change Today +0.80 / 0.32%
Volume 138.6K
As of 4:44 AM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Per Falholt

CSO and Executive Vice President of Research & Development, Novozymes A/S
AgeTotal Calculated CompensationThis person is connected to 14 board members in 3 different organizations across 3 different industries.

See Board Relationships
55kr11,600,000
As of Fiscal Year 2013

Background*

Mr. Per Falholt serves as an CSO and Executive Vice President of Research & Development at Novozymes A/S. Mr. Falholt joined Novozymes in 1984 as a Research Chemist in the Enzyme pilot plant. Mr. Falholt was appointed as a Manager of the Detergent Enzyme Division in 1987 and as a Director responsible for the application and development of new products for the detergent industry in 1990. He joined the Enzyme Development and Applications division in 1995 as a Director ...

Read Full Background

Corporate Headquarters*

Krogshoejvej 36
Bagsvaerd, -- 2880

Denmark

Phone: 45 44 46 00 00
Fax: 45 44 46 99 99

Board Members Memberships*

Director
Director

Education*

MS 1983
Technical University of Denmark

Other Affiliations*

Annual Compensation*

Salarykr3,900,000
Bonuskr1,100,000
Total Annual Compensationkr5,000,000

Stock Options*

Restricted Stock Awardskr5,400,000
All Other Compensationkr1,200,000
Exercised Options124,220
Total Number of Options245,435

Total Compensation*

Total Annual Cash Compensationkr6,200,000
Total Short Term Compensationkr5,000,000
Other Long Term Compensationkr6,600,000
Total Calculated Compensationkr11,600,000
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NZYMB:DC kr250.20 DKK +0.80

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Feike Sijbesma Chairman of Managing Board, Chief Executive Officer and Chairman of DSM Nutritional Products
Koninklijke DSM N.V.
€1.4M
Karl-Ludwig Kley Chairman of Executive Board
Merck KGaA
€5.4M
Richard Ridinger Chief Executive Officer
Lonza Group AG
--
John J. Nicols Chief Executive Officer, President and Director
Codexis, Inc.
$385.6K
Mark A. Emalfarb Founder, Chairman, Chief Executive Officer, President and Chairman of Nominating Committee
Dyadic International, Inc.
$375.0K
Compensation as of Fiscal Year 2013.

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVOZYMES A/S-B SHARES, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.